CARMAT

Company Description

---

CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company’s ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts.

The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States.

Year founded

---

2008

Served area

---

Worldwide

Headquarters

---

Immeuble l'Etendard 36 Avenue de l'Europe, 78141 Vélizy-Villacoublay Cedex – France

Shares outstanding

---

19,636,069

IPO

---

July 7, 2010

Stock exchange(s)

---

Euronext Paris